secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERCEPT PHARMACEUTICALS, INC. (—)
CIK:        0001270073
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001104659-23-115782
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 2.01, 3.01, 2.04, 3.03, 5.01, 5.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alfasigma completes acquisition of Intercept Pharmaceuticals for $19.00 per share
--------------------------------------------------------------------------------

- Tender offer closed with 74.5% of shares tendered; merger consummated under Section 251(h) without stockholder vote.
- Shares delisted from Nasdaq; Company will file Form 15 to suspend SEC reporting obligations.
- Board replaced by Alfasigma appointees: Francesco Balestrieri, Stefano Pasi, Michele Cera; Jerome Durso remains CEO, Balestrieri appointed President.
- 2.00% Convertible Senior Notes and 3.50% Convertible Senior Secured Notes now convertible into cash at $19.00 per share; holders have repurchase rights.
- Certificate of incorporation and bylaws amended and restated as of the merger effective time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/tm2330108d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer